These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27665129)

  • 41. Review: physical chemistry of solid dispersions.
    Janssens S; Van den Mooter G
    J Pharm Pharmacol; 2009 Dec; 61(12):1571-86. PubMed ID: 19958579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cocrystal Solubility Advantage and Dose/Solubility Ratio Diagrams: A Mechanistic Approach To Selecting Additives and Controlling Dissolution-Supersaturation-Precipitation Behavior.
    Cavanagh KL; Kuminek G; Rodríguez-Hornedo N
    Mol Pharm; 2020 Nov; 17(11):4286-4301. PubMed ID: 32815731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmaceutical cocrystals: a rising star in drug delivery applications.
    Panzade P; Wagh A; Harale P; Bhilwade S
    J Drug Target; 2024 Dec; 32(2):115-127. PubMed ID: 38164658
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physicochemical properties, form, and formulation selection strategy for a biopharmaceutical classification system class II preclinical drug candidate.
    Lohani S; Cooper H; Jin X; Nissley BP; Manser K; Rakes LH; Cummings JJ; Fauty SE; Bak A
    J Pharm Sci; 2014 Oct; 103(10):3007-21. PubMed ID: 25074668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Application of Modeling and Prediction to the Formation and Stability of Amorphous Solid Dispersions.
    DeBoyace K; Wildfong PLD
    J Pharm Sci; 2018 Jan; 107(1):57-74. PubMed ID: 28389266
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An investigation of the causes of cocrystal dissociation at high humidity.
    Eddleston MD; Thakuria R; Aldous BJ; Jones W
    J Pharm Sci; 2014 Sep; 103(9):2859-2864. PubMed ID: 24481664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmaceutical cocrystals: the coming wave of new drug substances.
    Brittain HG
    J Pharm Sci; 2013 Feb; 102(2):311-7. PubMed ID: 23192888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms by which moisture generates cocrystals.
    Jayasankar A; Good DJ; Rodríguez-Hornedo N
    Mol Pharm; 2007; 4(3):360-72. PubMed ID: 17488034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering.
    Loschen C; Klamt A
    J Pharm Pharmacol; 2015 Jun; 67(6):803-11. PubMed ID: 25851032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding Critical Quality Attributes for Nanocrystals from Preparation to Delivery.
    Peltonen L; Strachan C
    Molecules; 2015 Dec; 20(12):22286-300. PubMed ID: 26703528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir.
    Masuda T; Yoshihashi Y; Yonemochi E; Fujii K; Uekusa H; Terada K
    Int J Pharm; 2012 Jan; 422(1-2):160-9. PubMed ID: 22079714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The gut in the beaker: Missing the surfactants?
    Wilson CG; Halbert GW; Mains J
    Int J Pharm; 2016 Nov; 514(1):73-80. PubMed ID: 27863685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.
    Healy AM; Worku ZA; Kumar D; Madi AM
    Adv Drug Deliv Rev; 2017 Aug; 117():25-46. PubMed ID: 28342786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advanced methodologies for cocrystal synthesis.
    Douroumis D; Ross SA; Nokhodchi A
    Adv Drug Deliv Rev; 2017 Aug; 117():178-195. PubMed ID: 28712924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategies to address low drug solubility in discovery and development.
    Williams HD; Trevaskis NL; Charman SA; Shanker RM; Charman WN; Pouton CW; Porter CJ
    Pharmacol Rev; 2013 Jan; 65(1):315-499. PubMed ID: 23383426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications.
    Guo M; Sun X; Chen J; Cai T
    Acta Pharm Sin B; 2021 Aug; 11(8):2537-2564. PubMed ID: 34522597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
    Bittner B; Mountfield RJ
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):59-71. PubMed ID: 11865674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicomponent Pharmaceutical Cocrystals: A Novel Approach for Combination Therapy.
    Srivastava D; Fatima Z; Kaur CD
    Mini Rev Med Chem; 2018; 18(14):1160-1167. PubMed ID: 29512461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical formulations: insight, strategies, and practical considerations.
    Shah SM; Jain AS; Kaushik R; Nagarsenker MS; Nerurkar MJ
    AAPS PharmSciTech; 2014 Oct; 15(5):1307-23. PubMed ID: 24920522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of pharmaceutical excipients on drug disposition.
    Buggins TR; Dickinson PA; Taylor G
    Adv Drug Deliv Rev; 2007 Dec; 59(15):1482-503. PubMed ID: 18198495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.